Precigen (PGEN) Cash from Financing Activities (2012 - 2026)
Precigen's (PGEN) quarterly Cash from Financing Activities came in at $109000.0 in Q1 2026, up 116.05% year-on-year from $50450.6 in Q1 2025, and up 121.21% on a QoQ basis from -$514000.0 in Q4 2025.
Precigen (PGEN) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Cash from Financing Activities data on file, last reported at $109000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 116.05% year-over-year to $109000.0 in Q1 2026; TTM through Mar 2026 was $90.8 million, a 17.35% decrease from a year earlier, with the FY2025 full-year figure at $90.0 million, down 18.57% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $109000.0, up from -$514000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for PGEN reached as high as $93.0 million in Q3 2025 and fell as low as -$115.7 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $5.4 million across 5 years, with a median of -$138000.0 in 2022.
- Across the five-year window, Cash from Financing Activities plunged 49558.97% in 2022 and surged 27200.61% in 2023, its largest moves.
- Year by year, Cash from Financing Activities stood at -$39.3 million in 2022, then surged by 62.87% to -$14.6 million in 2023, then surged by 637.57% to $78.4 million in 2024, then sank by 100.66% to -$514000.0 in 2025, then jumped by 121.21% to $109000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $109000.0 in Q1 2026, -$514000.0 in Q4 2025, and $93.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn | 109,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,000.00 |
| Mar 31, 2026 | 109,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Sep 30, 2025 | 93.01 Mn |
| Sep 30, 2025 | 93.01 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -679,000.00 |
| Mar 31, 2025 | -679,000.00 |
| Dec 31, 2024 | 78.40 Mn |
| Dec 31, 2024 | 78.40 Mn |
| Sep 30, 2024 | 32.13 Mn |
| Sep 30, 2024 | 32.13 Mn |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2023 | -14.59 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | 44.17 Mn |
| Mar 31, 2023 | 44.17 Mn |